Elevation of miR-210 Expression and Mean Arterial Pressure as Early-onset Pre-eclampsia Biomarkers, while Elevation of Matrix Metalloproteinase-2 as Late-onset Pre-eclampsia Biomarker
Abstract
BACKGROUND: Pre-eclampsia has varying onset patterns, which are challenging to determine due to their association with diverse clinical parameters, including blood pressure regulation, vascular remodeling, and placental hypoxia. These parameters influence the expression of key biomarkers such as microRNAs, metalloproteinases, and arterial pressure indices. Therefore, understanding the associations is crucial for improving early diagnosis and management. This study was conducted to compare miR-210 expression, mean arterial pressure (MAP), and matrix metalloproteinase (MMP)-2 levels between early-onset pre-eclampsia (EOPE) and late-onset pre-eclampsia (LOPE).
METHODS: Pregnant women with EOPE (20–34 weeks) and LOPE (35 weeks to term) were included in this cross-sectional comparative study, and their blood samples were collected. miR-210 expression was quantified with reverse transcription polymerase chain reaction (RT-PCR), MAP was measured using sphygmomanometer, while MMP-2 levels were measured using enzyme-linked immunosorbent assay (ELISA).
RESULTS: miR-210 expression was more frequently observed in the EOPE group (87.5%) compared to the LOPE group (77.5%), with a significant difference identified between the two groups. The odds ratio for miR-210 expression in EOPE compared to LOPE was 2.03 (95% CI: 1.06–6.72). The MAP was notably higher in the EOPE group (121.15 mmHg) than in the LOPE group (116.15 mmHg), with a significant difference observed. Conversely, MMP-2 levels were significantly higher in the LOPE group (390.99 ng/mL) compared to the EOPE group (271.35 ng/mL).
CONCLUSION: There are significant differences in miR-210 expression, MAP and MMP-2 between EOPE and LOPE. These findings suggest that miR-210, MAP, and MMP-2 could be useful biomarkers for distinguishing between EOPE and LOPE, potentially guiding more effective management and intervention strategies.
KEYWORDS: miR-210, MAP, MMP-2, EOPE, LOPE, pre-eclampsia
Full Text:
PDFReferences
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018; 72(1): 24-43, CrossRef.
Van Der Merwe JL, Hall DR, Wright C, Schubert P, Grové D. Are early and late pre-eclampsia distinct subclasses of the disease what does the placenta reveal. Hypertens Pregnancy. 2010; 29(4): 457-67, CrossRef.
[NA]. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020; 135(6): e237-60, CrossRef.
Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L. Global pregnancy collaboration. Subtypes of preeclampsia: Recognition and determining clinical usefulness. Hypertension. 2021; 77(5): 1430-41, CrossRef.
Koushki M, Amiri Dash Atan N, Omidi-Ardali H, Rezaei Tavirani M. Assessment of correlation between miR-210 expression and pre-eclampsia risk: A meta-analysis. Rep Biochem Mol Biol. 2018; 7(1): 94-101, PMID.
Nikuei P, Davoodian N, Tahamtan I, Keshtkar AA. Predictive value of miR-210 as a novel biomarker for pre-eclampsia: A systematic review protocol. BMJ Open. 2016; 6(9): e011920, CrossRef.
Frazier S, McBride MW, Mulvana H, Graham D. From animal models to patients: The role of placental microRNAs, miR-210, miR-126, and miR-148a/152 in preeclampsia. Clin Sci. 2020; 134(8): 1001-25, CrossRef.
Jaszczuk I, Koczkodaj D, Kondracka A, Kwaśniewska A, Winkler I, Filip A. The role of miRNA-210 in pre-eclampsia development. Ann Med. 2022; 54(1): 1350-6, CrossRef.
Nikolov A, Popovski N. Role of gelatinases MMP-2 and MMP-9 in healthy and complicated pregnancy and their future potential as preeclampsia biomarkers. Diagnostics. 2021; 11(3): 480, CrossRef.
Bahabayi A, Yang N, Xu T, Xue Y, Ma L, Gu X, Wang Y, Jia K. Expression of matrix metalloproteinase-2,-7,-9 in serum during pregnancy in patients with pre-eclampsia: A prospective study. Int J Environ Res Public Health. 2022; 19(21): 14500, CrossRef.
Hu XQ, Zhang L. Hypoxia and mitochondrial dysfunction in pregnancy complications. Antioxidants. 2021; 10(3): 1-27, CrossRef.
Tang Z, Ji Y, Zhou S, Su T, Yuan Z, Han N, et al. Development and validation of multi-stage prediction models for pre-eclampsia: a retrospective cohort study on Chinese women. Front Public Health. 2022; 10: 911975, CrossRef.
Chen J, Khalil RA. Matrix metalloproteinases in normal pregnancy and pre-eclampsia. Prog Mol Biol Transl Sci. 2017; 148: 87-165, CrossRef.
Li W, Cui N, Mazzuca MQ, Mata KM, Khalil RA. Increased vascular and uteroplacental matrix metalloproteinase-1 and -7 levels and collagen type I deposition in hypertension in pregnancy: role of TNF-α. Am J Physiol Heart Circ Physiol. 2017; 313(3): H491-507, CrossRef.
Pineles BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with pre-eclampsia. Am J Obstet Gynecol. 2007; 196(3): 261.e1-261.e6, CrossRef.
Hossain MM, Sohel MM, Schellander K, Tesfaye D. Characterization and importance of microRNAs in mammalian gonadal functions. Cell Tissue Res. 2012; 349(3): 679-90, CrossRef.
Zhang Y, Fei M, Xue G, Zhou Q, Jia Y, Li L, et al. Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: New insights into molecular mechanisms for the disease. J Cell Mol Med. 2012; 16(2): 249-59, CrossRef.
Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: A scientific statement from the American Heart Association. Hypertension. 2022; 79(2): e21-41, CrossRef.
Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: Pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019; 15(5): 275-89. Erratum in: Nat Rev Nephrol. 2019; 15(6): 386, CrossRef.
Frazier S, McBride MW, Mulvana H, Graham D. From animal models to patients: the role of placental microRNAs, miR-210, miR-126, and miR-148a/152 in pre-eclampsia. Clin Sci (Lond). 2020; 134(8): 1001-25, CrossRef.
Sumawan H, Giantari I, Mubarika S, Hadiati DR, Pradjatmo H. Exosomal miRNAs as potential biomarkers for pre-eclampsia: miR-1283 has the highest expression, while miR-152-3p has the lowest expression. Indones Biomed J. 2024; 16(4): 387-96, CrossRef.
Pikir BS, Andrianto A, Suryawan IGR, Hermawan HO, Kartikasari DP, Harsoyo PM. microRNA-1 induces transdifferentiation of peripheral blood CD34+ cells into cardiomyocyte-like cells. Indones Biomed J. 2022; 14(3): 269-75, CrossRef.
Serudji J, Basyir V, Fadhillah T. Differentiating maternal angiogenesis factors between early and late-onset preeclampsia: higher sFlt-1 in early-onset preeclampsia, lower PlGF, and higher sFlt-1/PlGF ratio in late-onset preeclampsia. Mol Cell Biomed Sci. 2024; 8(3): 127-93, CrossRef.
Akbar MIAA, Sari IM, Ernawati, Aditiawarman. Plasma level of umbilical cord heme oxygenase-1 (HO-1) and neonatal outcome in early-onset and late-onset severe preeclampsia. Mol Cell Biomed Sci. 2019; 3(1): 54-9, CrossRef.
Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. SAGE Open Med. 2019; 7: 2050312119843700, CrossRef.
Anton L, Olarerin-George AO, Schwartz N, Srinivas S, Bastek J, Hogenesch JB, Elovitz MA. miR-210 inhibits trophoblast invasion and is a serum biomarker for pre-eclampsia. Am J Pathol. 2013; 183(5): 1437-45, CrossRef.
Rachmawati E, Sargowo D, Saputra IW, Riskiyah, Handirosiyanto I, Hakim AR, et al. Expression of plasma miRNA-133a is significantly lower in acute coronary syndrome (ACS) than in healthy/non-ACS subjects. Indones Biomed J. 2024; 16(5): 464-72, CrossRef.
Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 2018; 81: 241-330, CrossRef.
Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020; 21(24): 9739, CrossRef.
Fahmi MN, Pradjatmo H, Astuti I, Nindrea RD. Cytokines as prognostic biomarkers of epithelial ovarian cancer (EOC): A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021; 22(2): 315-23, CrossRef.
DOI: https://doi.org/10.18585/inabj.v17i2.3490
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
